Trial Profile
A 6-month, Double-blind, Randomized, Parallel-group, Multicenter Study Comparing Safety and Efficacy of Monotherapy With INT131 1 mg or 3 mg or Placebo Administered Orally Once Daily in Treatment Naïve Patients (Who Never Received Disease Modifying Treatment) With Relapsing-Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2017
Price :
$35
*
At a glance
- Drugs Ibrigampar (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors InteKrin Therapeutics
- 28 Oct 2017 Results of part 1 of this trial presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
- 24 Aug 2017 Status changed from active, no longer recruiting to completed.
- 27 Jun 2017 Results presented at the 3rd Congress of the European Academy of Neurology